Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...

Scientists discover that the CD74 protein could predict the effectiveness of immunotherapy, advancing colon cancer treatment.

With minimal blood loss and scarring, and faster recovery period, robotic surgeries are becoming game changers in the ...

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says.

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new stu ...

Artemisia herba-alba shows promise in combating colorectal cancer, offering new hope through its powerful medicinal ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...